Stock Analysis
Charles River Laboratories International, Inc. (CRL) Stock Analysis
Charles River Laboratories International, Inc. (CRL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Charles River Laboratories International, Inc. (CRL) currently has an AIQ Score of 38/100, indicating a bearish setup. Risk is the strongest factor at 50/100. Quality is the weakest current factor at 29/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CRL at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $278.26 |
| AIQ Score | 38/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Neutral |
| Market Cap | $13.6B |
| P/E Ratio | 28.52 |
| Forward P/E | — |
| EPS | -$0.03 |
| Revenue TTM | $1B |
| Dividend Yield | 0.00% |
| Beta | 1.38 |
| Volume | 767.56K |
| 52-week range | $144.26-$303.31 |
| RSI 14 | 35.62 |
| 50-Day SMA | $258.89 |
| 200-Day SMA | $202.43 |
| Analyst Price Target | $246.44 |
| Next Earnings | Nov 4, 2026 |
CRL
OverviewCRL Stock Analysis Summary
Charles River Laboratories International, Inc. (CRL) currently has an AIQ Score of 38/100, indicating a bearish setup. Risk resilience is the strongest factor at 50/100. Quality is the weakest current factor at 29/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, CRL has AIQ Score of 38/100 with Risk resilience base of 50/100 and fading Quality at 29/100. Wait for component alignment before adding exposure.
Risk resilience (50/100) leads while Quality (29/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.93% stock move · CRL classified in Medical - Diagnostics & Research.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CRL Bullish or Bearish Right Now?
CRL currently has a bearish overall setup. Risk Resilience is the strongest factor at 50/100, while Quality is weakest at 29/100. The current evidence suggests a defensive setup.
- - Price is +7.48% above its 50-day SMA.
- - Value is the current constraint at 42/100.
- - Momentum is weak at 35/100.
- - Analyst target implies -11.44% downside from the latest quote.
Current Consensus
CRL's Technical Analysis Consensus is currently Neutral, with 21 buy, 3 neutral, and 21 sell votes. CRL's 14-day RSI is 35.62, which places the stock in a weaker momentum range. CRL's beta is 1.38, indicating greater market sensitivity than the broad market.
What Changed in CRL?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the CRL Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CRL Decision Framework
Public evidence layers, setup checks, and risk context for Charles River Laboratories International, Inc..
Charles River Laboratories International, Inc. (CRL) Stock Analysis
Charles River Laboratories International, Inc. has an AIQ Score of 38/100 in a Defensive regime. Risk is strongest at 50/100. Beta is 1.38, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CRL is in a Defensive AIQ regime with score 38/100. |
| Signal Conflict | The primary conflict is that risk leads at 50/100 while quality lags at 29/100. |
| Factor Evidence | Momentum 35/100 · Value 42/100 · Quality 29/100 · Risk 50/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 50/100.
Momentum is 35/100 and RSI (14) is 35.6.
CRL is in a Defensive regime at 38/100.
Risk factor is 50/100 with beta 1.38 and annual volatility 45.98%.
Current conflict: risk leads at 50/100 while quality lags at 29/100.
CRL Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CRL Fundamentals
CRL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CRL Technical Analysis
CRL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CRL Stock Catalysts
Track CRL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CRL Dividend Analysis
CRL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CRL Financial Data
CRL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CRL Risk Analysis
CRL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CRL Stock News
CRL stock news, market tone, recent headlines, and catalyst context.
CRL vs Medical Devices Peers
Current peer cohort: CRL · DXCM · ENOV · EW · GEHC. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CRL Current stock | 38/100 | 42/100 | 35/100 | 50/100 | 1.45 | 45.98% | Current |
| DXCM Dexcom | 53/100 | 28/100 | 41/100 | 60/100 | 0.33 | 41.18% | CRL vs DXCM |
| ENOV Enovis Corporation | 47/100 | 74/100 | 24/100 | 40/100 | -0.47 | 63.37% | CRL vs ENOV |
| EW Edwards Lifesciences | 46/100 | 28/100 | 23/100 | 77/100 | 0.27 | 25.38% | CRL vs EW |
| GEHC GE HealthCare | 49/100 | 65/100 | 21/100 | 60/100 | -0.43 | 35.02% | CRL vs GEHC |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 27, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CRL
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CRL
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CRL Stock FAQ
What is CRL stock price today?
Charles River Laboratories International, Inc.'s current stock price is $278.26. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CRL bullish or bearish right now?
CRL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CRL's market cap?
CRL's market cap is $13.6B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CRL's current P/E ratio?
CRL's current P/E ratio is 28.52 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CRL's RSI?
CRL's 14-day RSI is 35.62 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CRL above its 50-day and 200-day moving averages?
CRL is 7.48% from its 50-day SMA and 37.46% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CRL's next earnings date?
CRL's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CRL pay a dividend?
CRL's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.